BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 14688112)

  • 41. Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.
    Findlow H; Borrow R; Hardelid P; Newton E; Frankland S; Naylor S; Miller E; Kaczmarski E; Read RC
    Clin Vaccine Immunol; 2011 Mar; 18(3):424-9. PubMed ID: 21248159
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
    Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
    Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.
    Read RC; Dull P; Bai X; Nolan K; Findlow J; Bazaz R; Kleinschmidt A; McCarthy M; Wang H; Toneatto D; Borrow R
    Vaccine; 2017 Jan; 35(3):427-434. PubMed ID: 27912986
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.
    Richmond P; Borrow R; Goldblatt D; Findlow J; Martin S; Morris R; Cartwright K; Miller E
    J Infect Dis; 2001 Jan; 183(1):160-3. PubMed ID: 11078484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine.
    Borrow R; Richmond P; Kaczmarski EB; Iverson A; Martin SL; Findlow J; Acuna M; Longworth E; O'Connor R; Paul J; Miller E
    FEMS Immunol Med Microbiol; 2000 May; 28(1):79-85. PubMed ID: 10767611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.
    Huo Z; Sinha R; McNeela EA; Borrow R; Giemza R; Cosgrove C; Heath PT; Mills KH; Rappuoli R; Griffin GE; Lewis DJ
    Infect Immun; 2005 Dec; 73(12):8256-65. PubMed ID: 16299322
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune responses following meningococcal serogroups A, C, Y and W polysaccharide vaccination in C2-deficient persons: evidence for increased levels of serum bactericidal antibodies.
    Brodszki N; Skattum L; Bai X; Findlow H; Borrow R; Jönsson G
    Vaccine; 2015 Apr; 33(15):1839-45. PubMed ID: 25707694
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meningococcal Serogroup A, B, C, W, X, and Y Serum Bactericidal Antibody Assays.
    Lucidarme J; Louth J; Townsend-Payne K; Borrow R
    Methods Mol Biol; 2019; 1969():169-179. PubMed ID: 30877677
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
    Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
    Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.
    Davis K; Valente Pinto M; Andrews NJ; Goldblatt D; Borrow R; Findlow H; Southern J; Partington J; Plested E; Patel S; Holland A; Matheson M; England A; Hallis B; Miller E; Snape MD
    Lancet Infect Dis; 2021 May; 21(5):688-696. PubMed ID: 33428870
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.
    Tappero JW; Lagos R; Ballesteros AM; Plikaytis B; Williams D; Dykes J; Gheesling LL; Carlone GM; Høiby EA; Holst J; Nøkleby H; Rosenqvist E; Sierra G; Campa C; Sotolongo F; Vega J; Garcia J; Herrera P; Poolman JT; Perkins BA
    JAMA; 1999 Apr; 281(16):1520-7. PubMed ID: 10227322
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
    Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Kinetics of immune responses to nasal challenge with meningococcal polysaccharide one year after serogroup-C glycoconjugate vaccination.
    Wing JB; Smart L; Borrow R; Findlow J; Findlow H; Heath AW; Read RC
    Clin Infect Dis; 2011 Jun; 52(11):1317-23. PubMed ID: 21596673
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule.
    Ladhani SN; Andrews NJ; Waight P; Hallis B; Matheson M; England A; Findlow H; Bai X; Borrow R; Burbidge P; Pearce E; Goldblatt D; Miller E
    Vaccine; 2015 Jan; 33(5):648-55. PubMed ID: 25510388
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.
    Lujan E; Partridge E; Giuntini S; Ram S; Granoff DM
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28566335
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
    Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
    Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and immune response after two-dose meningococcal C conjugate immunization in HIV-infected children and adolescents in Rio de Janeiro, Brazil.
    Frota ACC; Ferreira B; Harrison LH; Pereira GS; Pereira-Manfro W; Machado ES; de Oliveira RH; Abreu TF; Milagres LG; Hofer CB
    Vaccine; 2017 Dec; 35(50):7042-7048. PubMed ID: 29100708
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mode of splenectomy and immunogenicity of meningococcal vaccination in patients with hereditary spherocytosis.
    Stoehr GA; Luecken J; Zielen S; Eber SW; Borrow R; Rose MA
    Br J Surg; 2008 Apr; 95(4):466-71. PubMed ID: 18161897
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults.
    Campbell JD; Edelman R; King JC; Papa T; Ryall R; Rennels MB
    J Infect Dis; 2002 Dec; 186(12):1848-51. PubMed ID: 12447774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.